Logo image
Back
Clinical Presentation and In-Hospital Trajectory of Heart Failure and Cardiogenic Shock
Journal article   Open access   Peer reviewed

Clinical Presentation and In-Hospital Trajectory of Heart Failure and Cardiogenic Shock

Jaime Hernandez-Montfort, Manreet Kanwar, Shashank S. Sinha, A. Reshad Garan, Vanessa Blumer, Rachna Kataria, Evan H. Whitehead, Michael Yin, Borui Li, Yijing Zhang, …
JACC. Heart failure, v 11(2), pp 176-187
Feb 2023
DOI: https://doi.org/10.1016/j.jchf.2022.10.002
PMID: 36342421
Featured in Collection :   UN Sustainable Development Goals @ Drexel
url
https://doi.org/10.1016/j.jchf.2022.10.002View
Published, Version of Record (VoR) Restricted

Abstract

cardiogenic shock heart failure heart replacement therapy native heart survival
Heart failure–related cardiogenic shock (HF-CS) remains an understudied distinct clinical entity. The authors sought to profile a large cohort of patients with HF-CS focused on practical application of the SCAI (Society for Cardiovascular Angiography and Interventions) staging system to define baseline and maximal shock severity, in-hospital management with acute mechanical circulatory support (AMCS), and clinical outcomes. The Cardiogenic Shock Working Group registry includes patients with CS, regardless of etiology, from 17 clinical sites enrolled between 2016 and 2020. Patients with HF-CS (non–acute myocardial infarction) were analyzed and classified based on clinical presentation, outcomes at discharge, and shock severity defined by SCAI stages. A total of 1,767 patients with HF-CS were included, of whom 349 (19.8%) had de novo HF-CS (DNHF-CS). Patients were more likely to present in SCAI stage C or D and achieve maximum SCAI stage D. Patients with DNHF-CS were more likely to experience in-hospital death and in- and out-of-hospital cardiac arrest, and they escalated more rapidly to a maximum achieved SCAI stage, compared to patients with acute-on-chronic HF-CS. In-hospital cardiac arrest was associated with greater in-hospital death regardless of clinical presentation (de novo: 63% vs 21%; acute-on-chronic HF-CS: 65% vs 17%; both P < 0.001). Forty-five percent of HF-CS patients were exposed to at least 1 AMCS device throughout hospitalization. In a large contemporary HF-CS cohort, we identified a greater incidence of in-hospital death and cardiac arrest as well as a more rapid escalation to maximum SCAI stage severity among DNHF-CS. AMCS use in HF-CS was common, with significant heterogeneity among device types. (Cardiogenic Shock Working Group Registry [CSWG]; NCT04682483) [Display omitted]

Metrics

7 Record Views
64 citations in Web of Science
62 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Cardiac & Cardiovascular Systems
Logo image